SCHEMBL1963450

SCHEMBL1963450

CCOC(=O)c1cccc(Nc2ccc(OC)c(O[Si](C)(C)C(C)(C)C)c2)c1C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSV O60911 1/20 0.44
CTSL P07711 1/20 0.44
CDC25B P30305 5/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
MAPT P10636 5/20 0.43
DRD2 P14416 1/20 0.41
LMNA P02545 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
GAA P10253 1/20 0.40
IMPDH2 P12268 1/20 0.40
ALDH1A1 P00352 1/20 0.39
TOP1 P11387 1/20 0.39
PTGS2 P35354 1/20 0.39
CDC25A P30304 1/20 0.39
CDC25C P30307 1/20 0.39
KDM4E B2RXH2 1/20 0.39
POLB P06746 1/20 0.39
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1961719 0.88 CTSV (0.55) CTSVCTSLCDC25BSMN1; SMN2MAPT
SCHEMBL1963444 0.85 MAPT (0.42) CTSVCTSLSMN1; SMN2MAPTLMNA
SCHEMBL1964589 0.85 CTSV (0.52) CTSVCTSLCDC25BSMN1; SMN2MAPT
SCHEMBL1961347 0.77 AKR1C3 (0.57) CTSVCTSLCDC25BSMN1; SMN2MAPT
SCHEMBL1964822 0.77 CTSV (0.58) CTSVCTSLCDC25BSMN1; SMN2MAPT
SCHEMBL1964221 0.77 ALDH1A1 (0.53) CDC25BSMN1; SMN2MAPTLMNAMEN1
SCHEMBL1961759 0.76 CTSV (0.62) CTSVCTSLCDC25BSMN1; SMN2MAPT
SCHEMBL1964167 0.76 DHODH (0.48) CDC25BMAPTLMNAKMT2AALDH1A1
SCHEMBL1962918 0.75 CDC25B (0.59) CDC25BMAPTKMT2AGAACDC25A
SCHEMBL1964094 0.75 CDC25B (0.55) CDC25BSMN1; SMN2MAPTLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1919892-B1 ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORP (US) 2013-08-14 EP disclosed
US-8481568-B2 Isoindole-imide compounds and compositions comprising and methods of using the same CELGENE CORPORATION (US) 2013-07-09 US disclosed
US-20110144158-A1 ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME SEPRACOR INC. 2011-06-16 US disclosed
US-20070049618-A1 Isoindole-imide compounds and compositions comprising and methods of using the same CELGENE CORPORATION 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144158-A1 ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME SI, CYP3A5, CYP2D6 CTSV 1759/4885CTSL 1784/4885CDC25B 420/4885
US-20070049618-A1 Isoindole-imide compounds and compositions comprising and methods of using the same SI, CYP3A5, CYP2D6 CTSV 1759/4885CTSL 1784/4885CDC25B 420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.